| 1 |
33405070 | Lumasiran: First Approval. | 2021 Feb |
1 |
| 2 |
35071135 | Case Report: Sustained Efficacy of Lumasiran at 18 Months in Primary Hyperoxaluria Type 1. | 2021 |
1 |
| 3 |
29539912 | Re: An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. | 2017 May |
1 |
| 4 |
27847291 | RNA interference in the treatment of renal stone disease: Current status and future potentials. | 2016 Dec |
4 |
| 5 |
22342614 | High resolution crystal structure of rat long chain hydroxy acid oxidase in complex with the inhibitor 4-carboxy-5-[(4-chlorophenyl)sulfanyl]-1, 2, 3-thiadiazole. Implications for inhibitor specificity and drug design. | 2012 May |
2 |
| 6 |
21458484 | Exploring glycolate oxidase (GOX) as an antiurolithic drug target: molecular modeling and in vitro inhibitor study. | 2011 Jul 1 |
2 |
| 7 |
18215067 | Active site and loop 4 movements within human glycolate oxidase: implications for substrate specificity and drug design. | 2008 Feb 26 |
3 |
| 8 |
17669354 | Purification and characterization of recombinant human liver glycolate oxidase. | 2007 Sep 15 |
1 |
| 9 |
2223823 | The formation of oxalate from glycolate in rat and human liver. | 1990 Oct 12 |
2 |
| 10 |
16662946 | Synthesis of oxalic Acid by enzymes from lettuce leaves. | 1983 May |
1 |